Clinical Trial Update: Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of vandetanib (ZD6474) combined with fulvestrant (Faslodex) in non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• ZD6474 (vandetanib)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Carcinoma, Non Small Cell Lung | Phase 1 | Status: WITHDRAWN